What question did this study set out to answer?

To explore the effectiveness of JAK inhibition therapy for treating intractable cutaneous granulomatosis with unknown etiology.

March 15, 2026Open Access

JAK inhibition therapy for intractable cutaneous infectious granulomatosis with unknown etiology: a case report

Key Points

To explore the effectiveness of JAK inhibition therapy for treating intractable cutaneous granulomatosis with unknown etiology.
Case report detailing treatment with JAK inhibition using upadacitinib.
Patient presented with refractory granulomatosis and excessive immune response.
Treatment effects monitored over time.
Upadacitinib treatment resulted in notable improvement in symptoms.
Patient showed reduced immune response despite absence of identifiable pathogens.

Abstract

This case-report highlights a potential role for JAK inhibition, upadacitinib, in managing refractory cutaneous granulomatosis with an excessive immune response despite no identifiable pathogen and pathogen clearance.

JAK inhibition therapy for intractable cutaneous infectious granulomatosis with unknown etiology: a case report

Key Points

Abstract

Cite This Study